Max Healthcare Institute Ltd Q3 FY24 consolidated profit up at Rs. 289.34 Cr

Max Healthcare Institute has reported total income of Rs. 1380.99 crores during the period ended December 31, 2023

Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr

Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023

Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr

Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023

Glenmark partners Pfizer to launch Abrocitinib in India

Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India

Orchid Pharma's Exblifeb granted EMA approval

Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia

Mankind Pharma reports 55% YoY growth in PAT for Q3 FY24

Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth

Zydus Lifesciences launches Rexigo

This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India

Lupin Digital Health introduces digital therapeutics certificate for Cardiologists in India in collaboration with ACC

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation

Glenmark, Ichnos Sciences form ‘Ichnos Glenmark Innovation’ for new drug discovery in cancer treatment

This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors